SFI
SNDX icon

Susquehanna Fundamental Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-109,827
Closed -$2.61M – 1007
2024
Q1 		$2.61M Buy
+109,827
New +$2.45M 0.12% 200
2023
Q2 		– Sell
-26,678
Closed -$563K – 848
2023
Q1 		$563K Sell
26,678
-34,836
-57% -$867K 0.01% 648
2022
Q4 		$1.57M Buy
61,514
+16,270
+36% +$379K 0.03% 550
2022
Q3 		$1.09M Buy
+45,244
New +$1.02M 0.02% 783
2022
Q1 		$463K Buy
+26,666
New +$449K 0.01% 1108

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Susquehanna Fundamental Investments's SNDX Position: Q2 2024 in Review

Susquehanna Fundamental Investments sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 109,827 shares — an estimated $2.61M sold.

Susquehanna Fundamental Investments first reported a position in SNDX in Q1 2022 and held it in 5 quarters. The position peaked at $2.61M in Q1 2024. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

  • Susquehanna Fundamental Investments reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 109,827 Syndax Pharmaceuticals shares in Q2 2024, an estimated $2.61M.
  • Susquehanna Fundamental Investments first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Syndax Pharmaceuticals position peaked at $2.61M in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.